Evaxion Biotech
- Country
- π©π°Denmark
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 49
- Market Cap
- -
- Introduction
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen M?ller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
- Conditions
- Melanoma Stage IIIMelanoma Stage IV
- Interventions
- Drug: EVX-01Drug: Pembrolizumab 25 MG/ML
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Evaxion Biotech A/S
- Target Recruit Count
- 90
- Registration Number
- NCT05309421
- Locations
- π¦πΊ
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
π¦πΊSir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
π¦πΊBallarat Health Services (Grampians Health), Ballarat Central, Victoria, Australia
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
- Conditions
- Melanoma Stage IVMelanoma Stage III
- Interventions
- Drug: EVX-02A OR EVX-02BDrug: EVX-02ADrug: EVX-02B
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Evaxion Biotech A/S
- Target Recruit Count
- 15
- Registration Number
- NCT04455503
- Locations
- π¦πΊ
Ballarat Health Services, Drummond, Victoria, Australia
π¦πΊLiverpool Hospital, Goulburn, New South Wales, Australia
π¦πΊLinear Cancer Trials, Nedlands, Western Australia, Australia